Dr. Reddy’s Lab soars on getting CRL from USFDA for NuvaRing, Copaxone

22 Aug 2019

Dr. Reddy’s is currently trading at Rs. 2546.40, up by 40.60 points or 1.72% from its previous closing of Rs. 2503.40 on the BSE.

The scrip opened at Rs. 2527.00 and has touched a high and low of Rs. 2558.80 and Rs. 2503.40 respectively. So far 14373 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2965.20 on 02-May-2019 and a 52 week low of Rs. 2065.30 on 15-Feb-2019.

Last one week high and low of the scrip stood at Rs. 2567.50 and Rs. 2466.00 respectively. The current market cap of the company is Rs. 42309.20 crore.

The promoters holding in the company stood at 26.76%, while Institutions and Non-Institutions held 44.50% and 14.44% respectively.

Dr. Reddy's Laboratories has received complete response letter (CRL) from the US Food and Drug Administration (USFDA) for its versions of NuvaRing and Copaxone. NuvaRing is a birth control device and Copaxone (glatiramer acetate injection) is a multi-billion dollar drug and a prescription medicine used for the treatment of people with relapsing forms of multiple sclerosis.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Related Dr. Reddys Laboratories Ltd. Links:

Dr. Reddys Lab Share Price

4842.45 61.85 (1.29%) Apr 15, 18:01
1 Year Price Chart
Company Name CMP
Sun Pharma Inds. 632.95
Dr. Reddys Lab 4842.45
Lupin 1046.00
Piramal Enterprises 1715.00
Cadila Healthcare 504.00
View more..
Sensex vs Dr. Reddys Lab
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323